[Event Report] The First Meeting of Working Group 5 on Vaccine Research and Development, “Next Actions for the Development and Implementation of Immunization and Vaccination Policies” (November 4, 2021)
date : 11/18/2021
Tags: Vaccinations
![[Event Report] The First Meeting of Working Group 5 on Vaccine Research and Development, “Next Actions for the Development and Implementation of Immunization and Vaccination Policies” (November 4, 2021)](https://hgpi.org/en/wp-content/uploads/sites/2/480362ac0216ccd54a95db275fbedadb-1.jpg)
On November 4, 2021, HGPI held the first meeting of Working Group 5 on vaccine research and development for “Next Actions for the Development and Implementation of Immunization and Vaccination Policies.”
During this meeting, the members deepened their discussion on topics such as the issues in Japan’s vaccine R&D pipeline that were highlighted during the Coronavirus pandemic and the establishment of R&D pipelines in non-emergency situations for the 100 Days Mission, which aims to develop a vaccine within 100 days after the confirmation of a new infectious disease was agreed upon by the G7. There were active discussions on the measures necessary by the industry, government, academia, and civil society to promote vaccine R&D, which has low economic rationality and provide no incentives to the companies.
Due to the circumstances regarding the COVID-19 pandemic, this meeting was held online.
2021 Advisory Board Working Group 5 (Titles omitted; in alphabetical order by last name)
Members:
Ken J. Ishii (Professor, Division of Vaccine Science, Institute of Medical Science, The University of Tokyo/ Director, International Vaccine Design Center, Institute of Medical Science)
Masayuki Imagawa (Chief Executive, Japan Vaccine Industry Association/ Vice President & Head, Japan Vaccine Business Unit, Takeda Pharmaceutical Co., Ltd.)
Hiroshi Kasanuki (Specially Appointed Professor, Waseda University/ Advisor, Institute for Medical Regulatory Science, Waseda University)
Kengo Sonoda (General Manager, Development Department, R&D Division, KM Biologics Co., Ltd.)
Hideki Hasegawa (Director, Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases)
Yoshiharu Matsuura (Director, Center for Infectious Disease Education and Research (CiDER))
Shinji Matsumoto (Chair, Vaccines Working Team, EFPIA Japan)
Isao Miyairi (Professor, Faculty of Pediatrics, Hamamatsu University School of Medicine)
Yoshiaki Yamagishi (Associate Professor, Medical Center of Translational Research, Department of Medical Innovation, Osaka University)
Observer:
Yasuhiro Araki (Director, Office of Vaccine and Blood Products, Pharmaceuticals and Medical Devices Agency)
MC/Moderator:
Joji Sugawara (Manager, HGPI)
Opening Explanatory Introduction:
Ryoji Noritake (CEO/Board Member, HGPI)
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Announcement] HGPI Declares the Ministry of the Environment-led ‘Deco-Katsu Declaration’ and Participation in the ‘Deco-Katsu’ Supporters (October 16, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-11-27
[Registration Open] (Webinar) HGPI Cooperation with Lancet Countdown 2023 Japan Presentation “Climate Change as a Children’s Health Issue: The Latest Lancet Report Sounds the Alarm for Health Commitments” (December 14, 2023)
-
2023-11-28
[Event Report] The 1st Advisory Board Meeting for Patient and Public Involvement (PPI) Support Project “Necessary Steps for Promoting PPI in Policy Making” (October 3, 2023)
-
2023-11-29
[Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
-
2023-11-30
[Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)